Short-Term Xenical Treatment Benefits “Difficult To Define,” FDA Says
This article was originally published in The Tan Sheet
Executive Summary
Efficacy concerns surrounding GlaxoSmithKline's Xenical (orlistat) may prove to be a bigger hurdle to overcome than safety or self-selection issues as the firm pursues an Rx-to-OTC switch of the drug
You may also be interested in...
Glaxo’s Alli Advances Toward OTC Sale With “Approvable” Letter
GlaxoSmithKline's proposed Rx-to-OTC switch of the weight-loss drug Alli (orlistat 60 mg) is "approvable," according to a letter from FDA received by the firm April 6
Glaxo’s Alli Advances Toward OTC Sale With “Approvable” Letter
GlaxoSmithKline's proposed Rx-to-OTC switch of the weight-loss drug Alli (orlistat 60 mg) is "approvable," according to a letter from FDA received by the firm April 6
Glaxo’s Alli Advances Toward OTC Sale With “Approvable” Letter
GlaxoSmithKline's proposed Rx-to-OTC switch of the weight-loss drug Alli (orlistat 60 mg) is "approvable," according to a letter from FDA received by the firm April 6